MCRB - Seres Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

MCRB is currently covered by 7 analysts with an average price target of $17.1. This is a potential upside of $7.02 (69.64%) from yesterday's end of day stock price of $10.08.

Seres Therapeutics's activity chart (see below) currently has 63 price targets and 63 ratings on display. The stock rating distribution of MCRB is 77.78% BUY, 16.67% SELL and 5.56% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 49.71% with an average time for these price targets to be met of 167.9 days.

Highest price target for MCRB is $1.25, Lowest price target is $0.75, average price target is $4.67.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 20-Mar-2025. First documented stock forecast 22-Oct-2015.

Currently out of the existing stock ratings of MCRB, 14 are a BUY (77.78%), 3 are a SELL (16.67%), 1 are a HOLD (5.56%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$1.25

$-8.83 (-87.60%)

$1.25

1 months 8 days ago
(20-Mar-2025)

4/7 (57.14%)

$0.52 (71.23%)

263

Sell

$0.75

$-9.33 (-92.56%)

$1.25

1 months 14 days ago
(14-Mar-2025)

5/5 (100%)

$0.06 (8.70%)

80

Buy

5 months 14 days ago
(14-Nov-2024)

0/5 (0%)

$8.91 (146.31%)

Sell

$7

6 months 4 days ago
(24-Oct-2024)

1/1 (100%)

$0.56 (8.70%)

732

Buy

$12

$1.92 (19.05%)

$13

1 years 10 months 2 days ago
(26-Jun-2023)

4/11 (36.36%)

$6.6 (122.22%)

281

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is MCRB (Seres Therapeutics) average time for price targets to be met?

On average it took 167.9 days on average for the stock forecasts to be realized with a an average price target met ratio 49.71

Which analyst has the current highest performing score on MCRB (Seres Therapeutics) with a proven track record?

MARK BREIDENBACH

Which analyst has the most public recommendations on MCRB (Seres Therapeutics)?

Mark Breidenbach has 1 price targets and 6 ratings on MCRB

Which analyst is the currently most bullish on MCRB (Seres Therapeutics)?

Gbola Amusa with highest potential upside - $19.92

Which analyst is the currently most reserved on MCRB (Seres Therapeutics)?

Chris Shibutani with lowest potential downside - -$9.33

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?